Introduction. The role of autologous hematopoietic stem cell transplantation (autoHSCT) in adult patients with acute myeloid leukemia (AML) with poor prognosis factors is not completely defined. Purpose : to present the results of a multicenter prospective study of autoHSCT efficacy in AML patients with initially unfavorable prognostic factors. Materials and methods. From 2007 to 2014, 42 patients with primary AML with one or more poor prognosis factors were included in the study. AutoHSCT was performed in 16 patients (9 women) aged 20–57 years (median 38 years) without available compatible allogeneic (related or unrelated) donor. In order to identify the role of different prognostic factors the long-term results were analyzed. Results. With a median follow up of 49 months (range 5–86 months) 5-years overall survival, event-free survival and relapse-free survival were 47, 47 and 51 %, respectively. Rate of mortality associated with transplantation in 100 days and 2 years after autoHSCT reached 0 and 6 %, respectively. AML relapse was observed in 44 % of patients. Favorable prognostic influence of total body irradiation in conditioning regimens on the overall survival has been identified (р = 0.045). Conclusion . AutoHSCT in AML patients with initially poor prognosis factors has a long-term anti-tumor effect. In the absence of a fully compatible allogeneic donor, autoHSCT may be considered as an alternative treatment.
Chimerism monitoring after allogeneic bone marrow transplantation (alloBMT) using quantitative polymerase chain reaction (PCR) is important for assessment of efficiency of transplantation, early detection of recurrence, and timely treatment adjustment. This article presents cases of mixed chimerism after alloBMT.
The paper reports a review and analysis of the literature on preparation of hemopoietic stem cells (HSC) for allogeneic and autologic transplantation to adult patients with malignant neoplasms. Original data on the collection of HSC from different sources are presented along with prognostic factors for preparing sufficient amounts of HSC. The cells were obtained from a total of 122 subjects (298 procedures). It is shown that the choice of a HSC source and mobilization procedure on an individual basis ensures relatively safe HSC transplantation to all the patients for whom this operation is the treatment of choice.
In the present article the literary data of treatment a multiple myeloma is analyzed and the private experience of highdose chemotherapy is presented. Modern representations about possibilities of autologous and allogeneic stem cell transplantation during the period of supervision over the patients with multiple myeloma and the concept of authors about a role of stem cell transplantation are stated.
This article reviews the role of recombinant erythropoietin in the management of anemia in cancer patients based on literature data and our experience. We describe the problem of toxicity and report clinical recommendations and cautions for usage of drugs appertain to this pharmaceutical group.